Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
- About
Alpha Cognition Inc (ACOG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ACOG (1-star) is a SELL. SELL since 2 days. Profits (34.62%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $31.18
1 Year Target Price $31.18
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 17.56% | Avg. Invested days 25 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 160.20M USD | Price to earnings Ratio - | 1Y Target Price 31.18 |
Price to earnings Ratio - | 1Y Target Price 31.18 | ||
Volume (30-day avg) 1 | Beta 2.49 | 52 Weeks Range 3.75 - 11.40 | Updated Date 06/28/2025 |
52 Weeks Range 3.75 - 11.40 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.28 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28% | Return on Equity (TTM) -79.64% |
Valuation
Trailing PE - | Forward PE 26.88 | Enterprise Value 112563185 | Price to Sales(TTM) 33.52 |
Enterprise Value 112563185 | Price to Sales(TTM) 33.52 | ||
Enterprise Value to Revenue 38.44 | Enterprise Value to EBITDA -1.57 | Shares Outstanding 16019800 | Shares Floating 10409658 |
Shares Outstanding 16019800 | Shares Floating 10409658 | ||
Percent Insiders 1.59 | Percent Institutions 41.77 |
Analyst Ratings
Rating 1 | Target Price 31.18 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Alpha Cognition Inc
Company Overview
History and Background
Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for neurodegenerative diseases. They are focused on developing therapies for Alzheimer's Disease and other neurodegenerative conditions.
Core Business Areas
- Drug Development: Developing and commercializing pharmaceutical products for neurodegenerative diseases, with a primary focus on Alzheimer's disease.
- Preclinical Research: Conducting preclinical research to identify and develop new therapeutic candidates.
Leadership and Structure
Details on leadership team and organizational structure are not widely available in structured format, but typically consist of a CEO, CFO, Chief Medical Officer, and a Board of Directors.
Top Products and Market Share
Key Offerings
- ALPHA-1062 (Progranulin): Alpha Cognition's lead drug candidate is a small molecule prodrug that converts to progranulin. It is being developed as a potential treatment for neurodegenerative diseases. Clinical trials are underway. Market share data is not yet available. Competitors include companies developing other Alzheimer's treatments, such as Biogen (ADUHELM) and Eisai (LEQEMBI).
Market Dynamics
Industry Overview
The pharmaceutical industry focused on neurodegenerative diseases, particularly Alzheimer's disease, is characterized by high unmet needs and substantial market opportunities. The market is highly competitive, with numerous companies pursuing various therapeutic approaches.
Positioning
Alpha Cognition is positioned as a developer of novel treatments for neurodegenerative diseases. Their focus on ALPHA-1062 and its progranulin-enhancing mechanism provides a distinct competitive advantage. However, they are a smaller company competing with larger pharmaceutical players.
Total Addressable Market (TAM)
The global Alzheimer's disease market is projected to reach hundreds of billions of dollars in the coming years. Alpha Cognition aims to capture a portion of this TAM with successful development and commercialization of ALPHA-1062. The exact TAM capture will depend on clinical trial results and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach with ALPHA-1062
- Experienced management team
- Focus on a significant unmet medical need
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- High risk associated with clinical drug development
- Dependence on successful clinical trial outcomes
Opportunities
- Positive clinical trial results for ALPHA-1062
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline with new therapeutic candidates
Threats
- Failure of clinical trials
- Competition from other Alzheimer's treatments
- Regulatory hurdles and delays
Competitors and Market Share
Key Competitors
- LLY
- BIIB
- ESAIY
Competitive Landscape
Alpha Cognition faces intense competition from larger pharmaceutical companies with significantly greater resources. Their competitive advantage lies in their novel therapeutic approach.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth is measured by the advancement of clinical programs and securing funding.
Future Projections: Future growth is dependent on successful clinical trials and regulatory approvals for ALPHA-1062. Analyst estimates are not consistently available for companies at this stage.
Recent Initiatives: Recent initiatives include ongoing clinical trials for ALPHA-1062 and securing funding for these activities.
Summary
Alpha Cognition is a high-risk, high-reward clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases. Its lead drug candidate, ALPHA-1062, holds promise, but its success hinges on positive clinical trial outcomes. The company faces significant competition from larger pharmaceutical players and requires continuous funding to sustain its operations. Investors should be prepared for substantial volatility and a long-term investment horizon.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data may be limited due to the company's stage of development.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alpha Cognition Inc
Exchange NASDAQ | Headquaters Vancouver, BC, Canada | ||
IPO Launch date 2024-11-12 | CEO & Director Mr. Michael E. McFadden B.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.alphacognition.com |
Full time employees - | Website https://www.alphacognition.com | ||
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.